AbbVie licenses novel bispecific antibody from RemeGen for $5bn
New deal strengthens AbbVie's oncology portfolio, adding a new class…
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
List view / Grid view
New deal strengthens AbbVie's oncology portfolio, adding a new class…
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
The FDA has granted ODD to Telitacicept, produced by RemeGen,…
The FDA has granted ODD to Telitacicept, produced by RemeGen, for the treatment of myasthenia gravis.